Shire And Mylan Start New Era In Japan: Emerging Markets Roundup (Part 6)
This article was originally published in PharmAsia News
Executive Summary
Shire’s ADHD portfolio was a boost in Japan, but also carries high risk of generic cannibalization in the near future. Mylan and Pfizer ready to launch first generic tacrolimus in Japan next month.